DDInter1158 DDInter1254
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.
Mesalazine {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is bound by {v} (Compound) Nabumetone
Mesalazine {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Nabumetone
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Mesalazine {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is bound by {v} (Compound) Melatonin
Melatonin {u} (Compound) resembles {v} (Compound) Nabumetone
Mesalazine {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Naproxen
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Mesalazine {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Naproxen
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Mesalazine {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Naproxen
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Mesalazine {u} (Compound) causes {v} (Side Effect) Interstitial pneumonia
Interstitial pneumonia {u} (Side Effect) is caused by {v} (Compound) Cilostazol
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Mesalazine {u} (Compound) causes {v} (Side Effect) Weight increased
Weight increased {u} (Side Effect) is caused by {v} (Compound) Melatonin
Melatonin {u} (Compound) resembles {v} (Compound) Nabumetone
Mesalazine {u} (Compound) causes {v} (Side Effect) Jaundice cholestatic
Jaundice cholestatic {u} (Side Effect) is caused by {v} (Compound) Ranitidine
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nabumetone
Mesalazine (Compound) binds MPO (Gene) and MPO (Gene) is bound by Nabumetone (Compound)
Mesalazine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Nabumetone (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone
Mesalazine (Compound) binds MPO (Gene) and MPO (Gene) is bound by Melatonin (Compound) and Melatonin (Compound) resembles Nabumetone (Compound)
Mesalazine (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Naproxen (Compound) and PTGS2 (Gene) is upregulated by Naproxen (Compound) and Naproxen (Compound) resembles Nabumetone (Compound)
Mesalazine (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Naproxen (Compound) and Naproxen (Compound) resembles Nabumetone (Compound)
Mesalazine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Naproxen (Compound) and Naproxen (Compound) resembles Nabumetone (Compound)
Mesalazine (Compound) causes Interstitial pneumonia (Side Effect) and Interstitial pneumonia (Side Effect) is caused by Cilostazol (Compound) and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone
Mesalazine (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Melatonin (Compound) and Melatonin (Compound) resembles Nabumetone (Compound)
Mesalazine (Compound) causes Jaundice cholestatic (Side Effect) and Jaundice cholestatic (Side Effect) is caused by Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Nabumetone